StemCell Therapy

The pathophysiology of pain in neuropathy is complex and may be linked to sensory phenotypes. Quantitative sensory testing, a standardized method to evaluate sensory profiles in response to defined stimuli, assesses functional integrity of small and large nerve fiber afferents and central somatosensory pathways. It has revealed detailed insights into mechanisms of neuropathy, yet, it remains unclear if pain directly affects sensory profiles. The main objective of this study was to investigate sensory profiles in patients with various neuropathic conditions, including polyneuropathy, mononeuropathy, and lesions to the central nervous system, in relation to self-reported presence or absence of pain and pain sensitivity using the Pain Sensitivity Questionnaire.A total of 443 patients (332 painful and 111 painless) and 112 healthy participants were investigated. Overall, loss of sensation was equally prevalent in patients with and without spontaneous pain. Pain thresholds were equally lowered in both patient groups, demonstrating that hyperalgesia and allodynia is just as present in patients not reporting any pain. Remarkably, this was similar for dynamic mechanical allodynia. Hypoalgesia was more pronounced in painful polyneuropathy whereas hyperalgesia was more frequent in painful mononeuropathy (compared to painless conditions). Self-reported pain sensitivity was significantly higher in painful than in painless neuropathic conditions.Our results reveal the presence of hyperalgesia and allodynia in patients with central and peripheral lesions of the somatosensory system not reporting spontaneous pain. This shows that symptoms and signs of hypersensitivity may not necessarily coincide, and that painful and painless neuropathic conditions may mechanistically blend into one another.

PubMed

View post:
No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter...

More than half of women who underwent treatment for breast cancer experienced physical/functional complications involving an upper limb, according to results of a cross-sectional study published in Supportive Care in Cancer.1

Although a high incidence of posttreatment upper limb dysfunction has been previously reported in survivors of breast cancer, the aim of this study was to take a closer look at the underlying causes of this condition in women with a history of breast cancer.

Knowing what actually influences the development of upper limb dysfunction after breast cancer treatment can help healthcare professionals minimize the incidence of this complication, thus reducing the physical and functional impact of the disease and providing a better quality of life of survivors, the study authors commented.

This study involved adult women who had received breast cancer treatment between 2009 and 2016 at 1 of 2 institutions in Brazil.

Data related to sociodemographic characteristics and treatment history were collected during a patient interview and/or review of the patient medical record. The Disabilities of Arm, Shoulder and Hand (DASH) questionnaire was used to assess the impact of breast cancer treatment on the upper limb.2

Regarding the selection of the DASH questionnaire, the study authors explained that most of the instruments used to assess complications include physical examination with measurement of range of motion, muscle strength, and sensory capacity, and because they are limited to physical issues, many are unable to identify the level of independence and functionality for performing daily life activities related to the upper limbs.

They further clarified that the incorporation of patient-reported outcome measures into the DASH questionnaire also allowed for assessment of patient quality of life.

Other patient assessments included evaluations for the presence of lymphedema in the upper limb, breast skin sensitivity, paresthesia, pain, and scar adherence.

Of the 233 women included in this study, the mean patient age was 56.3 years. All patients underwent surgery for breast cancer with an average of approximately 5 years between surgical treatment and assessment. Lymphadenectomy was performed in 60.2% of patients, with the remaining patients having undergone either sentinel lymph node dissection or no surgical assessment of the lymph nodes. Approximately three-quarters of patients had received chemotherapy, radiation therapy, and were overweight/obese based on body mass index (BMI).

Key study findings included some level of upper limb dysfunction and evidence for sensory intercostobrachial nerve damage in 55.4% and 47.2% of patients, respectively.

Of note, analyses based on models adjusted for age and BMI showed that only paresthesia due to intercostobrachial nerve damage was significantly associated with upper limb dysfunction in these patients (odds ratio [OR], 1.96; 95% CI, 1.06-3.60; P =.03).

In summarizing the findings from this study, the study authors stated that upper limb dysfunction is a frequent complication after breast cancer treatment and may be associated with neuropathies due to changes in the intercostobrachial nerve pathway.

Reference

1. Siqueria TC, Fragoas SP, Pelegrini A, de Oliveira AR, Medeiros da Luz C. Factors associated with upper limb dysfunction in breast cancer survivors. Support Care Cancer. Published online August 17, 2020. doi:10.1007/s00520-020-05668-7

2. Beaton DE, Katz JN, Fossel AH, Wright JG, Tarasuk V, Bombardier C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther. 2001;14(2):128-146.

Visit link:
Neuropathy May Be Primary Cause of Upper Limb Dysfunction in Breast Cancer Survivors, Study Finds - Oncology Nurse Advisor

Diabetic neuropathy refers to the nerve damage caused due to diabetes. Diabetic neuropathy most often damages nerves in the legs and feet. However, it can injure nerve fibers throughout the body. Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes. Increasing diabetic population and growing awareness among people about diabetes and related complications are some of the major factors that drive the diabetic neuropathy market. Types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and other diabetic nerve damage. The peripheral diabetic neuropathy affects the feet and legs. It causes loss of sensation, and sometimes pain in the feet, legs, and hands. Autonomic diabetic neuropathy affects body functions such as heart rate, blood pressure, perspiration, and digestion. Proximal diabetic neuropathy affects thighs, hips, buttocks, and legs. Focal diabetic neuropathy affects the nerves, most often in the wrist, thigh, or foot. In addition, it also affects the nerves of the back, chest, and the nerves that control the eye muscles. Some of the factors that cause nerve damage in diabetes condition includes poor blood sugar control, kidney disease, smoking, excess weight, and length of time to have diabetes. However, anyone who has diabetes can develop neuropathy. Some symptoms of diabetic neuropathy are pain, tingling, numbness, and loss of feeling in the hands, arms, feet, and legs. The treatment options for diabetic neuropathy include drugs, radiotherapy, and physiotherapy.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/4795

The global diabetic neuropathy market is categorized based on medication, radiotherapy, and physiotherapy. Based on medication, the report covers antispasmodic, antidepressant, and others. Based on radiotherapy, the market comprises transcutaneous electrical nerve stimulation (TENS).

North America has the largest market for diabetic neuropathy, followed by Europe. This is due to the increasing number of patients with diabetes, rise in research and development activities, increasing awareness among people about diabetes and related complications, and improved healthcare infrastructure in the region. The diabetic neuropathy market in Asia is expected to experience high growth rate in the next few years. This is due to rising R&D activities for drug discovery and development, increasing government supports in the form of funding, growing awareness about diabetic neuropathy, and developing healthcare infrastructure in the region. In addition, growing demographics and economies in the developing countries such as India, China, and Japan are expected to lead growth in the diabetic neuropathy market in Asia.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/4795

Increasing prevalence of diabetes cases, growing, aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes and related nerve complications, and rise in R&D activities in drug discovery and developmemt are the key factors driving the global diabetic neuropathy market. However, high failure rate in clinical trials, stringent regulatory requirements, and longer approval time for drugs are some of the factors restraining the growth for global diabetic neuropathy market.

Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed in the global diabetic neuropathy market.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/4795

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to read the rest:
Demand for Diabetic Neuropathy Market to Witness Rapid Surge During the Period 2015 2021 - thedailychronicle.in

The research report on Peripheral Neuropathy Treatment market Size provides a thorough assessment of this business vertical. As per the study, the market is predicted to accumulate significant revenues and showcase a substantial growth rate during the estimated timeframe.

The Peripheral Neuropathy Treatment market report is a thorough investigation of the industry in terms of consumption and production. The report, based on the production facet, encompasses details regarding the manufacturing structure and profit margins of the renowned manufacturers. The price incurred by the companies to produce, store, and sell one unit of a product across the various geographies over the analysis period are also included in the study.

Speaking of the consumption aspect, the study details the consumption value and consumption volume of the products in question. Data pertaining to the individual sales price along with the import and export patterns spanning various territories are delivered in the report. Additionally, the report also predicts the production and consumption patterns over the assessment period.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/185890

Key pointers from the competitive landscape:

An outline of the regional landscape:

A brief overview of the product spectrum:

A summary of the application terrain:

In conclusion, the report evaluates the Peripheral Neuropathy Treatment market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are duly presented in the report.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/185890

Continued here:
Peripheral Neuropathy Treatment Market Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand and Forecast till 2025 - Express Journal

In 2029, the Neuropathy Pain Treatment market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Neuropathy Pain Treatment market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Neuropathy Pain Treatment market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Neuropathy Pain Treatment market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2641417&source=atm

Global Neuropathy Pain Treatment market report on the basis of market players

The report examines each Neuropathy Pain Treatment market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Neuropathy Pain Treatment market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Neuropathy Pain Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuropathy Pain Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuropathy Pain Treatment market.The following players are covered in this report:PfizerDepomedEli LillyEndoGrnenthal GroupArbor PharmaceuticalsNeuropathy Pain Treatment Breakdown Data by TypeCalcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthersNeuropathy Pain Treatment Breakdown Data by ApplicationRetail PharmaciesHospitalsOthers

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2641417&source=atm

The Neuropathy Pain Treatment market report answers the following queries:

The Neuropathy Pain Treatment market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2641417&licType=S&source=atm

Research Methodology of Neuropathy Pain Treatment Market Report

The global Neuropathy Pain Treatment market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Neuropathy Pain Treatment market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Neuropathy Pain Treatment market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read the original here:
Neuropathy Pain Treatment Market 10-Year Market Forecast and Trends Analysis Research Report - Scientect

The latest report on 2020-2029 Report on Global Neuropathy Pain Treatment Market by Player, Region, Type, Application and Sales Channel gives a broad assessment of the global Neuropathy Pain Treatment market by categorizing it in terms applications, types, and regions. The report gives a detailed analysis on competitive landscape and strategies that influenced the market in a positive way. Further, the report gives an overview of current market dynamics by studying various key segments based on the product, types, applications, end-to-end industries and market scenario.

Major Key Playersof Neuropathy Pain Treatment Market Report:Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Request a sample of this report @ https://www.regalintelligence.com/request-sample/159875

Market split by Type, can be divided into:

Calcium Channel Alpha 2-Delta Ligands

Serotonin-Norepinephrine Reuptake Inhibitors

Others

Market split by Application, can be divided into:

Retail Pharmacies

Hospitals

Others

Market split by Sales Channel, can be divided into:

Direct Channel

Distribution Channel

Market segment by Region/Country including:

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

Reach us to quote the effective price of this report @https://www.regalintelligence.com/check-discount/159875

Table of Contents

Chapter 1 Neuropathy Pain Treatment Market Overview

1.1 Neuropathy Pain Treatment Definition

1.2 Global Neuropathy Pain Treatment Market Size Status and Outlook (2014-2029)

1.3 Global Neuropathy Pain Treatment Market Size Comparison by Region (2014-2029)

1.4 Global Neuropathy Pain Treatment Market Size Comparison by Type (2014-2029)

1.5 Global Neuropathy Pain Treatment Market Size Comparison by Application (2014-2029)

1.6 Global Neuropathy Pain Treatment Market Size Comparison by Sales Channel (2014-2029)

1.7 Neuropathy Pain Treatment Market Dynamics (COVID-19 Impacts)

1.7.1 Market Drivers/Opportunities

1.7.2 Market Challenges/Risks

1.7.3 Market News (Mergers/Acquisitions/Expansion)

1.7.4 COVID-19 Impacts on Current Market

1.7.5 Post-Strategies of COVID-19 Outbreak

Chapter 2 Neuropathy Pain Treatment Market Segment Analysis by Player

2.1 Global Neuropathy Pain Treatment Sales and Market Share by Player (2017-2019)

2.2 Global Neuropathy Pain Treatment Revenue and Market Share by Player (2017-2019)

2.3 Global Neuropathy Pain Treatment Average Price by Player (2017-2019)

2.4 Players Competition Situation & Trends

2.5 Conclusion of Segment by Player

Chapter 3 Neuropathy Pain Treatment Market Segment Analysis by Type

3.1 Global Neuropathy Pain Treatment Market by Type

3.1.1 Calcium Channel Alpha 2-Delta Ligands

3.1.2 Serotonin-Norepinephrine Reuptake Inhibitors

3.1.3 Others

3.2 Global Neuropathy Pain Treatment Sales and Market Share by Type (2014-2019)

3.3 Global Neuropathy Pain Treatment Revenue and Market Share by Type (2014-2019)

3.4 Global Neuropathy Pain Treatment Average Price by Type (2014-2019)

3.5 Leading Players of Neuropathy Pain Treatment by Type in 2019

3.6 Conclusion of Segment by Type

Chapter 4 Neuropathy Pain Treatment Market Segment Analysis by Application

4.1 Global Neuropathy Pain Treatment Market by Application

4.1.1 Retail Pharmacies

4.1.2 Hospitals

4.1.3 Others

4.2 Global Neuropathy Pain Treatment Sales and Market Share by Application (2014-2019)

4.3 Leading Consumers of Neuropathy Pain Treatment by Application in 2019

4.4 Conclusion of Segment by Application

Chapter 5 Neuropathy Pain Treatment Market Segment Analysis by Sales Channel

5.1 Global Neuropathy Pain Treatment Market by Sales Channel

5.1.1 Direct Channel

5.1.2 Distribution Channel

5.2 Global Neuropathy Pain Treatment Sales and Market Share by Sales Channel (2014-2019)

5.3 Leading Distributors/Dealers of Neuropathy Pain Treatment by Sales Channel in 2019

5.4 Conclusion of Segment by Sales Channel

Chapter 6 Neuropathy Pain Treatment Market Segment Analysis by Region

6.1 Global Neuropathy Pain Treatment Market Size and CAGR by Region (2014-2029)

6.2 Global Neuropathy Pain Treatment Sales and Market Share by Region (2014-2019)

6.3 Global Neuropathy Pain Treatment Revenue and Market Share by Region (2014-2019)

6.4 North America

6.4.1 North America Market by Country

6.4.2 North America Neuropathy Pain Treatment Market Share by Type

6.4.3 North America Neuropathy Pain Treatment Market Share by Application

6.4.4 United States

6.4.5 Canada

6.4.6 Mexico

6.5 Europe

6.5.1 Europe Market by Country

6.5.2 Europe Neuropathy Pain Treatment Market Share by Type

6.5.3 Europe Neuropathy Pain Treatment Market Share by Application

6.5.4 Germany

6.5.5 UK

6.5.6 France

6.5.7 Italy

6.5.8 Russia

6.5.9 Spain

6.6 Asia-Pacific

6.6.1 Asia-Pacific Market by Country

6.6.2 Asia-Pacific Neuropathy Pain Treatment Market Share by Type

6.6.3 Asia-Pacific Neuropathy Pain Treatment Market Share by Application

6.6.4 China

6.6.5 Japan

6.6.6 Korea

6.6.7 India

6.6.8 Southeast Asia

6.6.9 Australia

6.7 South America

6.7.1 South America Market by Country

6.7.2 South America Neuropathy Pain Treatment Market Share by Type

Excerpt from:
Post-pandemic Analysis on Neuropathy Pain Treatment Market Likely to Emerge Over A Period Of 2020 2029 - Galus Australis

A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.

Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia led the research. She and her colleagues tested the effect of venom on clinical subtypes of breast cancer, using the venom from 312 honeybees and bumblebees from Perth Western Australia, Ireland and England.

No one had previously compared the effects of honeybee venom or melittin across all of the different subtypes of breast cancer and normal cells, Dr. Duffy said. We tested honeybee venom on normal breast cells, and cells from the clinical subtypes of breast cancer: hormone receptor positive, HER2-enriched, and triple-negative breast cancer.

Dr. Duffy explained that the goal of the research was ultimately to determine if honeybee venom and its component compound, melittin, had anti-cancer properties.

We found both honeybee venom and melittin significantly, selectively and rapidly reduced the viability of triple-negative breast cancer and HER2-enriched breast cancer cells, said Dr. Duffy. The venom was extremely potent.

Melittin, in particular, also had a surprising effect. Within 20 minutes, the compound was able to reduce the chemical messages of cancer cells that are necessary for growth and cell division.

We looked at how honeybee venom and melittin affect the cancer signaling pathways, the chemical messages that are fundamental for cancer cell growth and reproduction, and we found that very quickly these signaling pathways were shut down, said Dr. Duffy. Melittin modulated the signaling in breast cancer cells by suppressing the activation of the receptor that is commonly overexpressed in triple-negative breast cancer, the epidermal growth factor receptor, and it suppressed the activation of HER2 which is over-expressed in HER2-enriched breast cancer.

Western Australias Chief Scientist Professor Peter Klinken noted that this study significantly demonstrates the potential benefits of melittin, and overall, how compounds in nature can be utilized to combat human diseases.

The researchers note that studies will be necessary to formally assess the best way to deliver melittin to patients.

This is not the only positive news that has come out of the breast cancer treatment realm as of late. Athenex also announced on Sept. 1 that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application for oral paclitaxel and encequidar for the treatment of metastatic breast cancer, and it has been granted Priority Review.

We see oral paclitaxel as a potentially important alternative to IV infusions, especially during the current pandemic, as it may allow cancer patients to take the oral chemotherapy at home, said Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex. We believe the oral paclitaxel program validates our broader Orascovery platform, and we are committed to applying the technology to convert other IV chemotherapies into oral agents.

The NDA is based on data from a Phase 3 study of oral paclitaxel for the treatment of metastatic breast cancer. The trial was randomized and controlled, and looked at the safety and efficacy of oral paclitaxel monotherapy against IV paclitaxel monotherapy. It achieved its primary endpoint, demonstrating a statistically significant improvement in overall response rate, along with a lower neuropathy, compared to IV paclitaxel.

The FDA grants Priority Review to NDAs for potential drugs that, if approved, would make significant improvements to the way patients are treated for serious conditions, such as various types of cancer.

See the article here:
Could Bee Venom Be the Key to Treating Triple-Negative Breast Cancer? - PharmaLive

Erin Bryant, a physical therapist with Fyzical Therapy, said the body and the brain have the ability to heal with time. In Thieles case, she said, muscle memory and her former level of fitness will aid her recovery.

The therapy practice currently is working with three patients who have had COVID-19, including Thiele. All three cases are different, and all will require different treatment.

Theres no cookie-cutter for this, she said.

Christine Thiele, of Omaha, does a physical therapy session focusing on balance at WW Gym Wellness Workout in Omaha on Wednesday, August 26, 2020. Thiele had COVID-19 in the spring and is still struggling with lingering effects having to do with memory, balance and neuropathy.

Meanwhile, support groups for patients who have had COVID-19 have formed on Facebook and other forums. A group called Body Politic, which includes COVID-19 survivors, also has been involved in research.

Thiele has written about her situation on Facebook. She said doctors believe the virus triggered an autoimmune disease that has affected her mobility.

In the beginning, I was really trying to educate people to take this seriously, she said. Now its like, Look what its done to me. You guys really have to take it seriously.

Steve Schrader, too, has had a long road back.

Now 65, the La Vista man started in mid-March to experience symptoms, which he attributed to allergies. Those symptoms morphed into chest congestion and what he thought was a sinus infection. Schrader, who has asthma, battled it for a couple of weeks, as he usually does with chest congestion, including using a nebulizer.

See original here:
Even after the infection is gone, symptoms linger for COVID-19 'long-haulers' - Omaha World-Herald

MOUNT LAUREL, New Jersey, Sept. 3, 2020 /PRNewswire/ --On October 4-9, 2020, the American Neurological Association, for the first time in its 145-year history, is moving from a traditional meeting format to an interactive, virtual meeting experience. As always, the meeting will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology. In addition, ANA has announced that it is giving back to the neurological community by providing members with complimentary registration for ANA2020 and significantly reduced registration rates for non-members.

"We recognize that these are unprecedented times, and we are committed to providing meeting access to neurologists and neuroscientists around the world," explained ANA's Executive Director Nadine Goldberg, PhD, MS. "For over 100 years, we have brought together the best researchers and educators in this field, and this year will be no different in that respect, as we transition to an interactive, virtual event." She noted that it is important that all attendees register for the meeting in advance.

Many sessions held during the meeting will be pre-recorded, with live, interactive Q&A sessions following.This year's symposia dives into the science behind recent breakthroughs in our understanding and treatment of neurological disorders across a broad etiological spectrum and will feature talks and poster presentations with latest advances in translational neuroscience, neurobiology of disease, and academic neurology. The four plenary sessions are:

Also, on the schedule are 18 Special Interest Group (SIG) sessions, including Global Neurology, Traumatic Brain Injury, and Neurogenetics. New this year is the Emerging Scholar Lecture series, which is focused on providing junior investigators a platform to discuss their work. In addition, the Derek Denny-Brown Young Neurological Scholar Symposium will feature presentations from the 2020 Derek Denny-Brown awardees, the Wolfe Neuropathy Research Prize and the Grass Foundation-ANA Award in Neuroscience recipients.

ANA Social Justice Symposium to Address Inclusion and Diversity

The ANA is challenging itself to become a champion of 21st century academic neurology and neuroscience. Given that its past was marred by systemic racism, the ANA is working hard to find new ways to rectify these exclusionary practices. To meet these challenges, ANA is redoubling its efforts around inclusion and diversity through educating the neurological community and implementing organizational changes. In line with these efforts, the ANA is hosting its inaugural Social Justice Symposium prior to ANA2020. During this symposium attendees will learn about topics ranging from the impact of social determinants of health on adverse health outcomes for people of color, health policy, and will participate in interactive breakout sessions designed to develop actionable steps to address inequity within academic neurology and neuroscience.

A detailed Advance Program is online at https://2020.myana.org

Follow the meeting live using #ANA2020 on Twitter @TheNewANA1, on Facebook @AmericanNeurologicalAssociation, or on Instagram @ananeurology.

ABOUT THE ANA

The American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them.

For more information, visit http://www.myana.org or follow @TheNewANA1 on Twitter, @AmericanNeurologicalAssociation on Facebook, or @ananeurology on Instagram.

https://2020.myana.org

SOURCE American Neurological Association

Continue reading here:
American Neurological Association Hosts First-Ever All-Virtual Annual Meeting - PR Newswire India

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Exosome therapeutic marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @[emailprotected]

Read the original here:
Exosome Therapeutic Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 - Galus...

New York, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Veterinary Medicine Market by Product, Route of Administration, Animal Type, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 20202027" - https://www.reportlinker.com/p05955108/?utm_source=GNW

The veterinary medicine market accounted for $22,973 million in 2019, and is expected to reach $29,698 million by 2027, registering a CAGR of 4.6% from 2020 to 2027. Veterinary medicine is defined as a drug or other preparations employed in the treatment of animals. Furthermore, other preparations such as vaccines and medicated feed additives are also used to treat various medical conditions in animals. In addition, these medicines include different type of products such as anti-infective drugs, which are used to prevent, kill, or slow the growth of bacteria, fungi and other infection causing organisms. These medicines also include anti-inflammatory drugs, which are routinely used for relief of pain and inflammation associated with osteoarthritis, and other medical conditions in livestock and companion animals. Furthermore, parasiticide is another type of veterinary drug, which are employed in prevention or elimination of external and internal parasites such as fleas, ticks, and worms. Other than drugs, vaccines are also used in treatment of various medical conditions in animals. Some types of veterinary vaccines include inactivated vaccines, attenuated vaccines, and recombinant vaccine. Similarly, medicated feed additives are also used to cure medical conditions in livestock and companion animals. In addition, these different types of drugs are administered to animals through different routes such as oral, parenteral and topical. Furthermore, these drugs are used in treatment of companion animals such as dogs, cats and horses and are also used in treatment of livestock animals such as pigs, dairy cattle, beef cattle, and poultry. The major factors that contribute toward the growth of the veterinary medicine market include rise in number of pet owners and surge in livestock population across the globe. Furthermore, factors such as surge in prevalence of various medical conditions in animals and rise in demand for livestock products also boost growth of the veterinary medicine market. In addition, rise in animal healthcare expenditure is another major factor that fuels growth of the market. However, lack of veterinary infrastructure facilities in underdeveloped nations and stringent regulations associated with medicate feed additives restrict growth of the veterinary medicine market. Conversely, increase in awareness toward animal health offers a lucrative opportunity for the veterinary medicine market. The global veterinary medicine market is segmented on the basis of product, route of administration, animal type, distribution channel, and region to provide a detailed assessment of the market. By product, the market is divided into drugs, vaccines, and medicated feed additives. The drugs segment is further divided into anti-infective, anti-inflammatory, and parasiticide. In addition, the vaccines segment is divided into inactivated vaccines, attenuated vaccines, and recombinant vaccines. Similarly, the medicated feed additives segment is divided into amino acids and antibiotics. By route of administration, the market is classified into oral route, parenteral route, and topical route. By animal type, it is divided into companion animals and livestock animals. By distribution channel, it is classified into veterinary hospitals, veterinary clinics, and pharmacies & drug stores. By region, the veterinary medicine market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). The major players in the veterinary medicine market are Zoetis, Inc., Merck & Co., Inc. (Intervet International B.V.), Elanco Animal Health, Dechra Pharmaceuticals PLC, Ceva Sant Animale, Virbac., Vetoquinol S.A., Boehringer Ingelheim International GmbH., ADM Animal Nutrition, and Evonik Industries AG.

KEY BENEFITS FOR STAKEHOLDERS This report entails a detailed quantitative analysis along with the current global negative pressure wound therapy devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments. The market size and estimations are based on a comprehensive analysis of key developments in the industry. A qualitative analysis based on innovative products facilitates strategic business planning. The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments By Product o Drugs - Anti-infective - Anti-inflammatory - Parasiticide o Vaccines - Inactivated Vaccines - Attenuated Vaccines - Recombinant Vaccines o Medicated Feed Additives - Amino Acids - Antibiotics By Route of Administration o Oral Route o Parenteral Route o Topical Route By Route of Administration o Oral Route o Parenteral Route o Topical Route By Animal Type o Companion Animals o Livestock Animals

By Distribution Channel o Veterinary Hospital Pharmacies o Retail Veterinary Pharmacies By Region o North America - U.S. - Canada - Mexico o Europe - Germany - France - UK - Italy - Spain - Rest of Europe o Asia-Pacific - Japan - China - India - Australia - South Korea - Rest of Asia-Pacific

o LAMEA - Brazil - Saudi Arabia - South Africa - Rest of LAMEA List of key players profiled in the report: Zoetis, Inc. Merck & Co., Inc. (Intervet International B.V.) Elanco Animal Health Dechra Pharmaceuticals PLC Ceva Sant Animale Virbac. Vetoquinol S.A. Boehringer Ingelheim International GmbH. ADM Animal Nutrition Evonik Industries AG

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request) Pharmgate Inc. Bimedia, Inc.Read the full report: https://www.reportlinker.com/p05955108/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more here:
The veterinary medicine market accounted for $22,973 million in 2019, and is expected to reach $29,698 million by 2027, registering a CAGR of 4.6%...

Dr. Anthony S. Johnson, DVM, DACVECC, a leading veterinary professional and current Medical Director of the Veterinary Information Network (VIN), has been spotlighted in a new exclusive interview with Inspirery.

PLAINFIELD, IL / ACCESSWIRE / September 3, 2020 / The interview, which was published on August 27, 2020, can be found here on the official site. Inspirery features exclusive and in-depth interviews with accomplished entrepreneurs and executives from around the world.

The interview covered a broad range of business-related topics, including how Dr. Anthony S. Johnson launched his highly successful career in the veterinary profession, how he currently generates revenue, how he acquired his very first customer, and what marketing and new customer acquisition strategies are generating the most impact and return on investment.

In addition, Dr. Anthony S. Johnson provided insights on what he attributes his success to, what he believes the future holds for his business, what the toughest decision he's made in the last few months was, what advice he would give his younger self, and whether he would be willing to be a mentor to those aspiring to enter or establish themselves in the veterinary emergency and critical care field. Not surprising to anyone who knows him and his generous nature, he responded to this request with an emphatic yes.

Dr. Anthony S. Johnson also listed four business books that have inspired him over the years: Blue Ocean Strategy by Rene Mauborgne and W. Chan Kim, How Doctors Think by Jerome Groopman, The Checklist Manifesto by Atul Gawande, and Thinking, Fast and Slow by Daniel Kahneman. He also shared his enthusiasm about entering his 13th year of teaching an acclaimed and popular online class for new graduate veterinarians, which focuses on the basics of emergency room medicine.

"I have always enjoyed teaching, and am proud of the online course and the thousands of veterinarians that we have helped educate over the years," commented Dr. Anthony S. Johnson, who between 2009 and 2014 served as a Clinical Assistant Professor at Purdue University's College of Veterinary Medicine, where he taught a wide range of undergraduate, graduate and professional-level courses. "I believe that I have a duty and responsibility to give back to the profession by sharing my knowledge and experiences. The field of veterinary medicine is dynamic, and there are many exciting developments on the horizon driven by technologies like artificial intelligence and machine learning."

About Dr. Anthony S. Johnson

Dr. Anthony S. Johnson DVM, DACVECC, is a leading veterinary professional and educator who has filled a myriad of executive-level roles in veterinary centers across the U.S., including Critical Care Specialist, Emergency Department Head, and Co-Head. Currently, he is the Medical Director of the Veterinary Information Network (VIN). Dr. Johnson and his family recently relocated to the Chicago area from Carmel, Indiana. Known for his big smile, open heart, and wonderful sense of humor, when he is not working or spending time with his wife and their three children, Dr. Anthony S. Johnson enjoys occasional forays into woodworking, cooking, wine, reading, and writing. For more information about Anthony S. Johnson, please visit: https://anthonysjohnson.net/

Contact Information:

Anthony S. JohnsonEmail: Tony@VIN.comPhone: 503-522-3837

SOURCE: Dr. Anthony S. Johnson

View source version on accesswire.com: https://www.accesswire.com/604710/Leading-Veterinary-Professional-Dr-Anthony-S-Johnson-Spotlighted-in-New-Exclusive-Interview-with-Inspirery

View original post here:
Leading Veterinary Professional Dr. Anthony S. Johnson Spotlighted in New Exclusive Interview with Inspirery - Yahoo Finance

The state-of-the-art center steps up to aid the region's adoption network.

When longtime philanthropistsTina and George Skestos, founder of Homewood Corp., started working on a legacy project, they decided to address the troubles of a dog-rescue network burdened with overcrowding and costly medical care. After talking with dean Rustin Moore of the Ohio State University College of Veterinary Medicine, Columbus Humane CEO Rachel Finney and several veterinarians, the Skestoses noticed a problem of supply and demand. In Southern Ohio, rural shelters were overwhelmed by unwanted dogs and their medical care, yet Central Ohios counterparts could not keep up with the demand for adoptions.

It was being solved by putting dogs in a van and taking them from point A to point B, then causing more costs to the system as dogs transferred with health conditions, says Justin McKinniss, acting CEO of Gigis Shelter for Dogs, the Skestoses expansive center. George thought if you put a dollar in the middle of the system, it would save two dollars on each side.

Opened in 2018, the $4 million, 26,000-square-foot complex and its 19-member staff examine and treat up to 1,500 dogs annually. The dogs arrive from six partner shelters and typically spend three days at Gigis before being transferred to one of 17 adoption centers. On day one, they receive medical care. Day two, they are evaluated for their behavior, and on day three, they are spayed and neutered. During their stay, theyre kenneled in four separate wards to minimize the spread of disease. Dogs receive care at the state-of-the-art medical center featuring two surgical suites, two veterinarians, a dental suite, exam rooms, X-ray equipment and an isolated parvovirus treatment clinic.

The newest addition is a behavioral center directed by Meghan Herron, one of only three behavioral vets nationally within the shelter community. Dogs receive training to overcome behavioral issues and prepare them for adoption. The shelter now serves as a nationwide model, earning a spot among this years Petco Unsung Hero award finalists, alongside Gigis Shelter board president Jim Phieffer.

Beyond its own operation, Gigis invests in its partners facilities and equips them with vaccines, medical equipment and training. Gigis is the first of its kind, says Finney, who has worked with Gigis from the start. There were lots of transfer agencies, but this was the first that invested in the source shelters. Its not good enough to remove a dog from a [difficult] situation; its about helping agencies do a better job for all dogs.

Before Gigis, we would import litters of puppies with no medical or behavioral information and find out they had parvovirus once they arrive, says Kelsey Smucker, director of CHA Animal Shelter in Westerville. She explains that they would have to pay thousands of dollars to treat this highly infectious and deadly disease thats especially threatening to puppies. Now, Gigis has the facilitiesto quarantine and treat parvovirus as well as intervene with many other medical conditions.

When Gigis dogs arrive at our shelter, they go right on our adoption floor and often are adopted the first day, says Smucker.

While the shelter has garnered recognition, Tina Skestos says the biggest reward is seeing its adoptees, including several she and her husband pass on neighborhood walks with their Akita, Gigi, the shelters namesake. Its great to see the happy faces on these dogs and the joy they bring to these families, Tina says. All these dogs deserve a chance.

Originally posted here:
Gigis Shelter for Dogs is Coming to the Rescues - Columbus Monthly

A Cantonment woman has been charged with animal cruelty after allegedly performing injections on cats and collecting dead animals.

Selena Dunlap, 21, was charged with felony unlicensed practice of veterinary medicine and cruelty to animals.

Escambia County Animal Control responded to a home in the 1300 block of Tate Road after receiving a reported that Dunlap was injecting cats with food.

An animal control officer reported that she could see a couple of cats and dogs inside the home. When she asked about a kitten, Dunlap and her roommates said it was inside the trailer. Eddins asked Dunlap to show her what they were injecting the cat with when Dunlap brought out a bottle of sodium chloride.

When the officer was invited inside to see a kitten, she noted that the home was filled with old food, trash, cigarette butts and a dog kennel covered in blankets. Dunlap was holding the kitten, according to an arrest report, and said she had been giving it sugar water, watered down milk and antibotics.

Dunlap showed the animal control officer a needle she said she bought online, and the officer observed a magazine on a table with the title Secrets To Being a Vet Tech.

The officer said the kitten was not able to hold its head up. It was taken to the Escambia County Animal Shelter for care. It later died.

The report adds back in October 2019, Dunlaps dad contacted animal control stating she was living in a tent in the woods and collected dead animals and had live animals as well. When animal control responded to Dunlaps tent, she stated she had seven dogs and eight cats. Puppies were found covered in fleas.

Animal control removed 12 animals from Dunlap and ordered her to bury the dead animals.

Dunlap remained in the Escambia County Jail with bond set at $6,000.

Continued here:
Animal Control: Cantonment Woman Gave Injections To Kitten That Died; Collected Dead Animals - NorthEscambia.com

Four years ago, a casual hallway conversation between Virginia Tech work buddies Brian Huddleston and Heather Parrish led them to embark on a life-transforming journey.

According to Huddleston, a support technician on the IT team at theVirginia-Maryland College of Veterinary Medicine, Heather and I were work friends. We didnt go to each others houses or know each others families. We talked when we saw each other, but that was about it. I think I once bought her a bag of chips from the vending machine.

In exchange, Parrish, formerly an administrative assistant at the veterinary college who now works at theInstitute for Policy and Governancein theCollege of Architecture and Urban Studies, gave Huddleston one of her kidneys hardly an even trade by any stretch of the imagination.

I remember Brian once mentioning that he had a genetic kidney disorder, said Parrish, who was concerned about her colleague at the time. Huddleston, however, assured her that the disease seemed to be under control.

Doctors had first noticed a problem with Huddlestons kidney function when he was a teenager, but for years, he was able to lead a normal life. The situation took a more serious turn four years ago when a routine checkup revealed worrying changes in Huddlestons kidney function. He altered his diet; and once again, the disease was brought to heel.

I was able to manage things for a long time by being careful, Huddleston said. Despite his best efforts, a bout of Henoch-Schonlein purpura, or HSP, a relatively common illness that typically affects children, sidelined him in early 2019. In most people, HSP resolves on its own after a few weeks, but because of Huddlestons already-compromised kidney function, the disease sent his body into a tailspin.

Kidneys filter out waste and release compounds that regulate the bodys bone health, blood pressure, and creation of red blood cells essential functions. Huddlestons kidneys had lost these crucial filtering abilities.

At that point, my kidneys were just useless bags of fluid, Huddleston said with characteristic wry humor. I was admitted to the hospital, and I started hemodialysis. Even after I was discharged, I had to spend three days a week hooked up to a machine just to stay alive.

The average life expectancy of a person on dialysis is about 10 years. Without a new kidney, the 41-year-old husband might not outlive his eight beloved rescue dogs and cats.

During his illness, Huddleston continued sharing updates on his Facebook page. By then, Parrish had left her job at the veterinary college, but she still stayed in touch with former colleagues through social media.

I saw people posting things on Brians page like Let me know if theres anything I can do to help, and I thought, There is something I can do. If Huddleston were going to survive, he didnt need cheery get-well cards or flowers: He needed a new kidney.

Through online research, Parrish discovered that, typically, more than 110,000 men, women, and children are on the national transplant waiting list and that more than 80 percent of those people are waiting for a new kidney. It was a long line, much too long for her liking.

Parrish reached out to the transplantation team at the University of Virginia (UVA) and began the arduous process of match testing. The early signs were good. Parrish and Huddleston shared a blood type and had compatible antibodies. Further testing revealed that Parrishs kidneys were in tip-top shape.

It was comforting to Parrish to know that even if she and Huddleston werent a match, her donation could start a donor chain allowing her kidney to be matched with someone else while another kidney could then be made available for Huddleston.

Working with Virginia Techs Human Resources, Parrish arranged for paid leave under the Bone Marrow/Organ Donor policy that provides time off to eligible employees donating bone marrow or an organ; in any calendar year, the policy also includes recuperation for up to 30 days. This additional leave, along with solid support from her boss, her co-workers, and her family, eased the way for surgery to be scheduled in March 2020.

Donors and their families do not pay for medical expenses associated with organ and tissue donation. And while much of Huddlestons care was covered by insurance, expenses such as ongoing visits to UVA and a hotel stay for his wife when he was hospitalized in Charlottesville were not.

The staff association at the veterinary college stepped in to help. This is just what we do, said Tami Quesenberry, a licensed veterinary technician who co-chaired a massive fundraising effort, including a goods and services auction that raised nearly $10,000 for Huddleston. The situation brought members of this great big veterinary family together like never before, she said.

Continue reading here:
All That and A Bag of Chips: VA Tech Employee Donates Kidney to Save Co-worker's Life - The Roanoke Star

Veterinary care in the field

The School of Veterinary Medicine was taking care of four-legged patients: more than 1,000 in the field and more than two dozen in the Veterinary Medical Teaching Hospital. Officials said they are purposely trying to do most of their first aid in the field, because they are forced by the pandemic to limit hospital capacity.

On Aug. 25, the Veterinary Emergency Response Team deployed a four-person team one faculty veterinarian and two resident veterinarians, and one student on a search and rescue operation in the Vacaville foothills. The team also performed wellness examinations on animals sheltered in place.

At the campus hospital, the team has treated 11 alpacas, six goats, five horses, three llamas, three cats and two sheep.

Read more about the veterinary schools response to the wildfires.

UC Davis put out the welcome mat Friday, offering short-term emergency housing for campus affiliates including faculty, staff and registered students and their families who had been impacted by evacuations or lost their homes due to the wildfires.

For campus affiliates who need somewhere to stay until evacuation orders are lifted and they can return home, the university is offering stays of up to five days. For campus affiliates who have lost their homes, the university can help explore options for longer-term housing solutions.

UC Davis sustained losses, too, as the LNU Lightning Complex struck four of the universitys natural reserves: Quail Ridge, Stebbins Cold Canyon, Cahill Riparian Preserve and McLaughlin Natural Reserve, all in the vicinity of Lake Berryessa west of Davis.

With access limited, officials had not yet been able to assess the full extent of the damage to facilities and research projects. Shane Waddell, though, has seen some of what happened at Quail Ridge, where he is the reserve director. Fire claimed his home and eight tent cabins.

His family evacuated Aug. 19, while he stayed behind to monitor the fire. As the flames drew closer, he decided to leave but not until he had told his neighbors on the Quail Ridge peninsula it was time to depart for their own safety.

Peggy Fiedler, executive director of the UC Natural Reserve System, said UC reserve managers and stewards up and down the state had been absolutely heroic in their efforts to save life and property.

Read more about what happened at the UC Davis reserves and four other UC reserves.

Read more:
Responding to Record-Setting Wildfires - UC Davis

The University of Georgia once again posted new highs in research and development expenditures, nearly topping the $500 million mark and exceeding last years R&D total by almost 4%, illustrating the rapidly growing research enterprise at UGA.

Fueled by new advancements in infectious diseases, plant sciences, behavioral research, animal health, informatics and many other disciplines, UGA posted $495 million in R&D expenditures in fiscal year 2020, which ended June 30. For six of the past seven years, the university has reported annual increases in R&D, which has grown by 41% during that time.

UGA has focused strategically on growing its research enterprise through faculty hiring initiatives, capital projects dedicated to research (such as the ongoing effort to modernize and expand Science Hill, including the I-STEM Research Building currently under construction), and enhanced administrative support to faculty seeking external research funding.

Growing research and innovation is central to the mission of this university, and the future of the research enterprise at UGA has never been brighter, said President Jere W. Morehead. I am pleased that our strategic investments are paying off, and I look forward to the many life-saving and world-changing advancements that will result.

UGA faculty earned dozens of multi-million-dollar awards last year, including potentially the biggest in the universitys history. Ted Ross, a GRA Eminent Scholar and director of the Center for Vaccines and Immunology in the College of Veterinary Medicine, received a major NIH contract to develop a more effective flu vaccine. Establishing one of several prestigious and multi-institutional Collaborative Influenza Vaccine Innovation Centers, the contract is slated to be worth $130 million over seven years. Once the coronavirus pandemic hit, NIH directed Ross to expand the scope of this project to include the testing of potential COVID-19 vaccines, working with colleagues at both academic and industry labs.

UGA received other eight-figure awards in 2020 as well. Professor David Okech in the School of Social Work was awarded nearly $20 million from the U.S. Department of State to find ways to combat human trafficking. Distinguished Research Professor Jessie Kissinger in the Franklin College of Arts and Sciences received two awards worth a combined $16 million to develop specialized health informatics databases.

These large awards complement thousands of other research grants and contracts, large and small, earned by faculty from across UGAs 17 schools and colleges, nearly a third of which received awards totaling more than $10 million.

The University of Georgias growth in external research funding demonstrates the increasing recognition of our faculty, nationally and internationally, said S.JackHu, senior vice president for academic affairs and provost. In a broad range of fields and often working together across traditional academic disciplines, they are making a positive impact on our state and world.

UGA recently launched its Innovation District initiative in part to capitalize on the universitys research growth and provide new pathways for discoveries to reach the public. In each of the past six years, UGA has been a Top 5 university for the number of new products brought to market. UGA now ranks No. 10 in the nation for innovation impact as measured by the George W. Bush Institute/Opus Faveo Innovation Development.

UGA faculty have made significant progress in expanding their externally funded research activities, which allows us to better serve the citizens of Georgia and the world, said David Lee, vice president for research. I congratulate the faculty on their continuing progress. To maximize the impact of our growing research engine, the university has invested in the expertise and resources to bring new discoveries to market whenever that is appropriate, and the Innovation District is an exciting new example.

See more here:
UGA nears $500M in R&D expenditures in record-breaking year - University of Georgia

Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet into the equine market by making IsoPet available to treat solid tumors in horses. The most common tumors are equoids and sarcomas. This is an important expansion of Vivos business plan.

Our regional clinic in the state of Missouri for IsoPet therapy has agreed to expand into IsoPet therapy on solid tumors in horses. The initial few therapies will be subsidized, while we fine-tune the details of the treatment technique, but we are confident that IsoPet will be the best option available to treat these tumors.

Dr. Mike Korenko stated, Treating large tumors in large animal is a special challenge, but with our experience on large tumors in small animals we have the data necessary to proceed to this next step. This is a potentially lucrative market as Isopet provides a highly differentiated treatment alternative for horses suffering with solid tumors.

About Vivos Inc. (OTCQB: RDGL)

Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the companys proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

Radiogel is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

Radiogel also has a short half-life delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members. The Isopet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019. In February of 2020, we announced the University of Missouri Veterinary Health Center will serve as a regional clinic for Isopet.

In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that Isopet is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval was required for treating skin cancer, which is the largest market sector. Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet to University animal hospitals and private veterinary clinics.

Isopet for treating animals uses the same technology as RadioGel for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.Michael K. Korenko, Sc.D.President & CEOMKorenko@RadioGel.com

See the original post here:
Vivos Inc Initiates IsoPet Therapy of Horses Addressing Unmet Need for the Treatment of Equine Tumors - GlobeNewswire

In an effort to safeguard the health and safety of all during the COVID-19 pandemic, the Human Animal Bond Research Institute (HABRI) has transformed its annual Pet Night on Capitol Hill to a virtual week-long event. Now called Pet Week on Capitol Hill, the event will take place Sept. 8-10.

Pets have become even more important during the coronavirus pandemic, said Steven Feldman, executive director of HABRI. Pet Week on Capitol Hill will feature conversations with members of Congress and pet care leaders about the importance of pet ownership in America.

The first night will include a session about the importance of pets in America, presented by Feldman and Mark Cushing, author of Pet Nation: The Love Affair That Changed America.

The session, Lifesaving Pet-Related Legislation: A Discussion of Important Initiatives That Will Help Keep Pets and People Safe, Healthy and Happy Together, will take place the following day on Sept. 9. Presenters include Kurt Venator, DVM, Ph.D., chief veterinary officer at Nestl Purina PetCare; Nicole Forsyth, president and CEO of RedRover; and Nicole Lanahan, executive director of Got Your Six Support Dogs.

Also taking place that evening is the session One Health Act: The Role of Veterinary Medicine in Preventing Future Pandemics, presented by Representative Kurt Schrader (OR-5).

On Sept. 10, Steven King, president and CEO of American Pet Products Association (APPA), and Dave Bolen, industry specialist at Graham Partners, will present Pet Ownership and Pet Industry Economics in the Post-COVID World.

Following, Susanne Kogut, president of the Petco Foundation, will present COVID-19 Impact on Pet Fostering and Adoption. The Animal Health Institute (AHI) will then present Cutest Pets on Capitol Hill: Honoring the Cutest Congressional Companions from Both Sides of the Aisle.

We plan to be back with Pet Night on Capitol Hill next year to celebrate in person with the pets that we love so much, Feldman said. Until then, we hope that virtual Pet Week will be helpful, and that all of the participating pet care organizations will serve as valuable resources for our friends on Capitol Hill.

Details on Pet Week on Capitol Hill can be found here.

Read more on PPN's coverage of this topic:

Continue reading here:
Pets to Take on Capitol Hill in Virtual Week-Long Event - PetProductNews.com

RESEARCH TRIANGLE PARK With $814,714 in initial federal funding,RTI InternationalandDuke Universitys Human Vaccine Institutewill collaborate in a global project to identify viruses and other pathogens in wildlife that could cause disease in people, such as the coronavirus responsible for the COVID-19 pandemic.

RTI and Duke will operate the Coordinating Center for 10 other newly established Centers for Research in Emerging Infectious Diseases(CREID), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The agency awarded 11 grants with a total first-year value of about $17 million to establish the centers and will provide about $82 million over five years to support them.

The impact of the COVID-19 pandemic serves as a potent reminder of the devastation that can be wrought when a new virus infects humans for the first time, said NIAID Director Anthony S. Fauci, M.D. The CREID network will enable early warnings of emerging diseases wherever they occur, which will be critical to rapid responses. The knowledge gained through this research will increase our preparedness for future outbreaks.

CREID will be part of global network of multidisciplinary investigations into how and where viruses and other pathogens emerge from wildlife and cross into humans to cause disease.

Each center in the network will involve collaborations with peer institutions in the United States and 28 other countries. Research projects will include surveillance studies to identify previously unknown causes of febrile (fever-creating) illnesses in humans; find the animal sources of viral or other disease-causing pathogens; and determine which genetic or other changes make these pathogens capable of infecting humans.

CREID investigators also will develop reagents and diagnostic assays to improve detection of emerging pathogens and study human immune responses to new or emerging infectious agents.

The breadth of research projects in the CREID network will allow for study of disease spillover in multiple phases of the process: where pathogens first emerge from an animal host; at the borders between wild and more populated areas, where human-to-human transmission occurs; and, finally, in urban areas, where epidemic spread can occur.

Each CREID center will focus efforts on one or more regions of the world. In Central and South America, for example, studies will include investigations of several arthropod-borne viruses (arboviruses) including the ones that cause Zika virus disease, chikungunya and dengue. In East and Central Africa, focus pathogens will include Rift Valley fever virus and the coronavirus that causes Middle East respiratory syndrome. In West Africa, in addition to arboviruses, projects are slated on Ebola virus and Lassa virus. In Asia and Southeast Asia, investigators will conduct research on coronaviruses and arboviruses.

In every region, investigators will be poised to study any newly emerging pathogen, dubbed pathogen X.

The CREID Coordinating Center run by RTI and Duke will support network-wide activities such as data management, outbreak research response and quality control for biospecimens, assays and reagents. It will also administer a pilot research program for early career investigators.

The principal investigators for the CREID Coordinating Center will be Donald Brambilla, Ph.D., of RTI and Tony Moody, M.D., of Dukes School of Medicine.

Our ability to support rapid and efficient research response to an emerging infectious disease outbreak is paramount to shortening the duration and reducing morbidity and mortality, said Brambilla, senior research statistician at RTI.

Moody, associate professor of pediatrics at Duke, said, During the past six months, weve seen the impact of the COVID-19 pandemic across the globe. By creating and supporting an infrastructure that allows rapid response to infectious disease outbreaks by researchers and by leveraging what we have learned and are learning from research organizations across the globe, we aim to shorten future outbreaks.

As the operational hub for the CREID Network, the RTI-Duke Coordinating Center team offers expertise in supporting administration and management of data and scientific programs, according to the CREID website. The CREID CC has extensive experience in international outbreak research response, including field experience responding to complex outbreaks.

The RTI-Duke team will also maintain and grow existing relationships with domestic and international collaborators, including Ministries of Health and local research institutions, according to the website. Additionally, the team will facilitate and coordinate relevant outreach to engage new partners.

The RTI-Duke team will support 10 CREID centers based at Scripps Research Institute; EcoHealth Alliance; University of California, Berkeley; University of California, Davis, School of Veterinary Medicine; Washington State University; Institut Pasteur; University of Texas Medical Branch, Galveston; University of Washington, Seattle; Washington University School of Medicine; and the University of Texas Medical Branch, Galveston.

(C) N.C. Biotech Center

Read the original:
RTI, Duke team up to identify threats like coronavirus in wildlife that might affect humans - WRAL Tech Wire